A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Stopped Early discontinuation based on strategic sponsor decision not driven by any safety concerns
Conditions
- Classic Hodgkin Lymphoma
- Diffuse Large B-cell Lymphoma
Interventions
- DRUG: THOR-707
- DRUG: Pembrolizumab
Sponsor
Sanofi
Collaborators